Pharmaceutical preparations Stocks List

This page shows information about the 50 largest pharmaceutical preparations industry stocks including Eli Lilly and Company, Johnson & Johnson, Novo Nordisk A/S, and AbbVie.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$872.98 +7.98 (+0.92%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$871.65 -1.33 (-0.15%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The stock has a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards its future performance.
  • Recent trading activity shows the stock price at $827.41, reflecting a significant increase of $16.98 in a single day, which may suggest strong market interest.
  • Eli Lilly and Co has announced a quarterly dividend increase to $1.50, up from $1.30, which represents a yield of 0.73%. This increase can attract income-focused investors.

Cons of Eli Lilly and Company

  • The stock has a high P/E ratio of 89.45, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • The company has a debt-to-equity ratio of 2.03, suggesting that it relies heavily on debt financing, which can be risky if market conditions change.
  • Insider ownership is low at 0.13%, which may indicate a lack of confidence from those within the company regarding its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$828.74 billion
P/E Ratio
74.55
Consensus Rating
Moderate Buy
Consensus Price Target
$997.50 (+14.3% Upside)
Volume
2.53 million shares
Average Volume
3.85 million shares
Today's Range
$856.11
$877.78
50-Day Range
$726.24
$878.09
52-Week Range
$711.40
$972.53
Dividend Yield
0.60%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$155.23 -0.90 (-0.58%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$155.38 +0.15 (+0.09%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson reported earnings per share (EPS) of $2.04 for the latest quarter, exceeding the consensus estimate of $1.99, indicating strong financial performance and effective management.
  • The company has a robust return on equity of 34.35%, which suggests that it is efficient in generating profits from its equity investments, making it an attractive option for investors seeking high returns.
  • With a quarterly revenue of $22.52 billion, which is up 5.3% year-over-year, Johnson & Johnson demonstrates consistent growth, appealing to growth-oriented investors.

Cons of Johnson & Johnson

  • The company’s EPS has decreased from $2.29 in the same quarter last year to $2.04, indicating a decline in profitability, which may concern potential investors.
  • Johnson & Johnson's payout ratio is currently 74.59%, suggesting that a significant portion of its earnings is being distributed as dividends, which could limit funds available for reinvestment in growth opportunities.
  • Analysts have mixed ratings on the stock, with some lowering their price targets, which may indicate uncertainty about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$373.73 billion
P/E Ratio
23.34
Consensus Rating
Moderate Buy
Consensus Price Target
$170.67 (+9.9% Upside)
Volume
7.75 million shares
Average Volume
9.07 million shares
Today's Range
$154.27
$155.66
50-Day Range
$142.07
$156.18
52-Week Range
$140.68
$168.85
Dividend Yield
3.23%
Novo Nordisk A/S stock logo

3. Novo Nordisk A/S NYSE:NVO

$81.78 -1.96 (-2.34%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$80.91 -0.87 (-1.06%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent upgrades from multiple analysts, including a "strong-buy" rating from BNP Paribas, indicate strong market confidence in Novo Nordisk's future performance.
  • The stock has a consensus target price of $145.25, suggesting significant upside potential from its current trading price of $82.64.
  • Institutional investors have shown increased interest, with DAVENPORT & Co LLC boosting its holdings by 75.1%, reflecting confidence in the company's growth prospects.

Cons of Novo Nordisk A/S

  • The stock has recently experienced a decline of 2.1%, which may raise concerns about short-term volatility and market sentiment.
  • With a PE ratio of 26.74, the stock may be considered overvalued compared to industry peers, potentially limiting future price appreciation.
  • The company has a quick ratio of 0.75, which is below 1, indicating potential liquidity issues in meeting short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$366.99 billion
P/E Ratio
24.86
Consensus Rating
Moderate Buy
Consensus Price Target
$145.25 (+77.6% Upside)
Volume
6.42 million shares
Average Volume
9.27 million shares
Today's Range
$80.53
$82.36
50-Day Range
$78.74
$111.69
52-Week Range
$78.17
$148.15
Dividend Yield
0.83%
AbbVie stock logo

4. AbbVie NYSE:ABBV

$193.06 +1.23 (+0.64%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$193.16 +0.10 (+0.05%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has a strong market capitalization of $335.60 billion, indicating a robust financial position and potential for growth.
  • The company reported a return on equity of 257.91%, showcasing its ability to generate significant profit from shareholders' equity, which is a positive indicator for investors.
  • AbbVie has a current stock price around $172.24, which is below its 52-week high of $207.32, suggesting potential for price appreciation.

Cons of AbbVie

  • AbbVie has a high debt-to-equity ratio of 9.64, which suggests that the company is heavily reliant on debt financing, potentially increasing financial risk.
  • The company missed its earnings per share estimate by $0.82, reporting $2.16 instead of the expected $2.98, which may raise concerns about its profitability.
  • AbbVie has a quick ratio of 0.54, indicating that it may struggle to meet short-term liabilities without selling inventory, which could be a red flag for liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$341.16 billion
P/E Ratio
80.44
Consensus Rating
Moderate Buy
Consensus Price Target
$208.35 (+7.9% Upside)
Volume
4.52 million shares
Average Volume
6.02 million shares
Today's Range
$190.39
$194.37
50-Day Range
$169.19
$192.95
52-Week Range
$153.58
$207.32
Dividend Yield
3.40%
AstraZeneca stock logo

5. AstraZeneca NASDAQ:AZN

$74.43 +1.70 (+2.34%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$75.06 +0.63 (+0.84%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Capitalization
$230.81 billion
P/E Ratio
32.93
Consensus Rating
Buy
Consensus Price Target
$89.75 (+20.6% Upside)
Volume
5.71 million shares
Average Volume
5.28 million shares
Today's Range
$73.03
$74.60
50-Day Range
$64.44
$72.73
52-Week Range
$60.76
$87.68
Dividend Yield
1.35%
Abbott Laboratories stock logo

6. Abbott Laboratories NYSE:ABT

$130.48 -0.96 (-0.73%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$131.31 +0.83 (+0.64%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Market Capitalization
$226.31 billion
P/E Ratio
17.06
Consensus Rating
Moderate Buy
Consensus Price Target
$133.06 (+2.0% Upside)
Volume
4.70 million shares
Average Volume
6.97 million shares
Today's Range
$129.24
$130.80
50-Day Range
$110.96
$132.07
52-Week Range
$99.71
$132.50
Dividend Yield
1.84%
Novartis stock logo

7. Novartis NYSE:NVS

$106.98 -0.77 (-0.71%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$107.02 +0.03 (+0.03%)
As of 02/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Market Capitalization
$218.67 billion
P/E Ratio
18.19
Consensus Rating
Reduce
Consensus Price Target
$123.38 (+15.3% Upside)
Volume
2.48 million shares
Average Volume
1.98 million shares
Today's Range
$106.36
$107.50
50-Day Range
$96.77
$109.84
52-Week Range
$92.35
$120.92
Dividend Yield
2.27%
Merck & Co., Inc. stock logo

8. Merck & Co., Inc. NYSE:MRK

$85.71 -0.83 (-0.96%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$85.90 +0.19 (+0.22%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has a strong institutional ownership, with 76.07% of its stock held by institutional investors, indicating confidence in the company's long-term performance.
  • The stock is currently trading at $90.99, which may present a buying opportunity for investors looking for value, especially considering its one-year high of $134.63.
  • Recent analyst ratings show a consensus of "Moderate Buy" with an average target price of $122.67, suggesting potential upside for investors.

Cons of Merck & Co., Inc.

  • Merck's stock has recently experienced volatility, trading down 8.8% in a single day, which may raise concerns about short-term performance.
  • Analysts have adjusted price targets downward, with Citigroup lowering its target from $130.00 to $125.00, indicating potential challenges in meeting previous expectations.
  • There is a sell rating from one analyst, which could signal caution for investors considering entering or holding a position in Merck.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$216.82 billion
P/E Ratio
12.74
Consensus Rating
Moderate Buy
Consensus Price Target
$117.06 (+36.6% Upside)
Volume
14.78 million shares
Average Volume
14.21 million shares
Today's Range
$85.61
$86.67
50-Day Range
$86.52
$103.79
52-Week Range
$85.61
$134.63
Dividend Yield
3.68%
Pfizer stock logo

9. Pfizer NYSE:PFE

$25.46 -0.07 (-0.27%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$25.52 +0.06 (+0.24%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Market Capitalization
$144.28 billion
P/E Ratio
18.06
Consensus Rating
Moderate Buy
Consensus Price Target
$31.92 (+25.4% Upside)
Volume
31.60 million shares
Average Volume
38.45 million shares
Today's Range
$25.17
$25.62
50-Day Range
$25.23
$27.12
52-Week Range
$24.48
$31.54
Dividend Yield
6.66%
Sanofi stock logo

10. Sanofi NASDAQ:SNY

$54.56 +0.66 (+1.22%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$54.57 +0.01 (+0.02%)
As of 02/12/2025 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi recently reported earnings per share of $1.57, significantly exceeding the consensus estimate of $0.22, indicating strong financial performance and effective management.
  • The company has shown a year-over-year revenue increase of 12.3%, demonstrating growth potential and resilience in its business operations.
  • With a current stock price of $52.48, Sanofi is trading near its one-year high of $58.97, suggesting positive market sentiment and potential for further appreciation.

Cons of Sanofi

  • Sanofi's revenue for the latest quarter was $13.44 billion, falling short of analyst estimates of $16.59 billion, which may raise concerns about future growth prospects.
  • The company has a quick ratio of 0.65, which is below 1, indicating potential liquidity issues in meeting short-term obligations without selling inventory.
  • Despite a solid earnings report, the price-to-earnings ratio of 26.28 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$138.46 billion
P/E Ratio
21.91
Consensus Rating
Buy
Consensus Price Target
$60.00 (+10.0% Upside)
Volume
2.23 million shares
Average Volume
2.56 million shares
Today's Range
$53.76
$54.87
50-Day Range
$45.89
$54.56
52-Week Range
$45.22
$58.97
Dividend Yield
2.78%
Vertex Pharmaceuticals stock logo

11. Vertex Pharmaceuticals NASDAQ:VRTX

$453.20 -2.02 (-0.44%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$453.48 +0.29 (+0.06%)
As of 02/12/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated has recently reported strong earnings, with an earnings per share (EPS) of $4.38, surpassing analysts' expectations of $3.61. This indicates robust financial performance and potential for future growth.
  • The stock price of Vertex Pharmaceuticals Incorporated is currently at $482.55, reflecting a 2.6% increase in recent trading. A rising stock price can signal investor confidence and market interest.
  • Analysts have a consensus rating of "Moderate Buy" for Vertex Pharmaceuticals Incorporated, with a target price averaging $502.58. This suggests that many analysts believe the stock has room for growth.

Cons of Vertex Pharmaceuticals

  • Despite recent earnings growth, Vertex Pharmaceuticals Incorporated has a negative net margin of 4.52%, which indicates that the company is currently spending more than it earns, raising concerns about long-term profitability.
  • The stock has a high price-to-earnings (P/E) ratio of -232.00, suggesting that the stock may be overvalued relative to its earnings, which could deter value-focused investors.
  • Vertex Pharmaceuticals Incorporated has experienced fluctuations in analyst ratings, with some firms downgrading their ratings and price targets, which can create uncertainty in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$116.71 billion
P/E Ratio
-227.74
Consensus Rating
Moderate Buy
Consensus Price Target
$505.96 (+11.6% Upside)
Volume
1.14 million shares
Average Volume
1.58 million shares
Today's Range
$446.00
$455.66
50-Day Range
$396.64
$488.44
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Bristol-Myers Squibb stock logo

12. Bristol-Myers Squibb NYSE:BMY

$56.17 +0.23 (+0.41%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$56.17 0.00 (0.00%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which positions the company well in the growing pharmaceutical market.
  • The company has demonstrated significant institutional investor interest, with Valley National Advisers Inc. increasing its stake by 494% recently, indicating confidence in the company's future performance.
  • As of the latest trading session, Bristol-Myers Squibb's stock price is $59.15, reflecting a solid market capitalization of approximately $119.97 billion, which suggests stability and potential for growth.

Cons of Bristol-Myers Squibb

  • The company has a high debt-to-equity ratio of 2.83, which indicates that it relies heavily on debt financing. This could pose risks if the company faces financial difficulties or if interest rates rise.
  • Despite a strong product lineup, the pharmaceutical industry is highly competitive, and Bristol-Myers Squibb may face challenges from generic drugs and new entrants that could impact its market share.
  • The stock has experienced fluctuations, with a twelve-month low of $39.35, suggesting potential volatility that could deter conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$113.92 billion
P/E Ratio
-12.71
Consensus Rating
Hold
Consensus Price Target
$57.86 (+3.0% Upside)
Volume
8.50 million shares
Average Volume
10.94 million shares
Today's Range
$55.45
$56.54
50-Day Range
$55.35
$60.61
52-Week Range
$39.35
$61.10
Dividend Yield
4.32%
Zoetis stock logo

13. Zoetis NYSE:ZTS

$173.99 -0.30 (-0.17%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$177.38 +3.39 (+1.95%)
As of 02/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. has shown strong financial performance, reporting a revenue of $2.40 billion for the latest quarter, exceeding analysts' expectations of $2.29 billion. This indicates robust demand for its products and effective management.
  • The company recently increased its quarterly dividend from $0.43 to $0.50, reflecting a commitment to returning value to shareholders. This represents an annualized dividend of $2.00, providing a yield of 1.17%, which can be attractive for income-focused investors.
  • Analysts have a consensus rating of "Buy" for Zoetis Inc., with a target price averaging $215.00. This suggests potential upside for investors based on current market conditions.

Cons of Zoetis

  • Despite strong performance, the stock has recently traded down $1.90, indicating potential volatility and market concerns that could affect short-term investment returns.
  • The company has a debt-to-equity ratio of 1.26, which suggests that it has a relatively high level of debt compared to its equity. This could pose risks, especially in a rising interest rate environment.
  • Some analysts have lowered their price targets for Zoetis Inc., with Stifel Nicolaus reducing their target from $210.00 to $180.00. This could indicate a more cautious outlook on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.50 billion
P/E Ratio
32.70
Consensus Rating
Buy
Consensus Price Target
$214.00 (+23.0% Upside)
Volume
2.89 million shares
Average Volume
2.63 million shares
Today's Range
$171.53
$174.12
50-Day Range
$162.24
$178.84
52-Week Range
$144.80
$200.53
Dividend Yield
1.15%
GSK stock logo

14. GSK NYSE:GSK

$36.15 +0.08 (+0.22%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$36.08 -0.07 (-0.18%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc has a current stock price of $34.29, which is significantly lower than the consensus target price of $43.25, indicating potential for price appreciation.
  • The company recently increased its quarterly dividend to $0.3928, representing an annualized dividend of $1.57 and a yield of 4.58%. This increase reflects GSK's commitment to returning value to shareholders.
  • GSK has a market capitalization of $71.06 billion, which suggests a stable and established presence in the pharmaceutical industry, potentially providing a safer investment compared to smaller companies.

Cons of GSK

  • GSK has experienced recent downgrades from multiple analysts, including a shift from "buy" to "hold" ratings, which may indicate a lack of confidence in the stock's short-term performance.
  • The company has a high dividend payout ratio of 95.45%, which suggests that a large portion of its earnings is being distributed to shareholders. This could limit the funds available for reinvestment in growth opportunities.
  • GSK's stock has a 12-month high of $45.92, which may indicate that it is currently trading closer to its peak, potentially limiting upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$74.92 billion
P/E Ratio
22.74
Consensus Rating
Moderate Buy
Consensus Price Target
$43.25 (+19.6% Upside)
Volume
3.62 million shares
Average Volume
4.64 million shares
Today's Range
$35.53
$36.26
50-Day Range
$32.12
$37.67
52-Week Range
$31.72
$45.92
Dividend Yield
4.06%
Regeneron Pharmaceuticals stock logo

15. Regeneron Pharmaceuticals NASDAQ:REGN

$663.86 -1.60 (-0.24%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$670.09 +6.23 (+0.94%)
As of 02/12/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is $672.98, which is significantly lower than its 12-month high of $1,211.20, indicating potential for price recovery and growth.
  • Regeneron Pharmaceuticals, Inc. has a strong market capitalization of $73.95 billion, suggesting stability and a solid position in the biopharmaceutical industry.
  • The company boasts a low debt-to-equity ratio of 0.09, indicating a strong balance sheet and lower financial risk, which is attractive to investors seeking stability.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced a significant decline from its 12-month high, which may indicate underlying issues or market volatility that could deter potential investors.
  • Barclays recently lowered their price objective for the stock from $1,080.00 to $1,065.00, which may reflect concerns about the company's near-term performance.
  • Despite a strong market cap, the price-to-earnings (P/E) ratio of 16.65 may suggest that the stock is overvalued compared to its earnings, which could be a red flag for value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.95 billion
P/E Ratio
17.34
Consensus Rating
Moderate Buy
Consensus Price Target
$973.13 (+46.6% Upside)
Volume
1.29 million shares
Average Volume
972,353 shares
Today's Range
$655.85
$670.98
50-Day Range
$665.46
$788.00
52-Week Range
$642.00
$1,211.20
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

16. Takeda Pharmaceutical NYSE:TAK

$13.26 -0.18 (-1.34%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$13.40 +0.14 (+1.03%)
As of 02/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited recently reported quarterly earnings of $0.42 EPS, exceeding the consensus estimate of $0.34 by $0.08, indicating strong financial performance and effective management.
  • The company has a market capitalization of approximately $42.18 billion, reflecting its significant size and stability in the pharmaceutical industry.
  • Takeda Pharmaceutical Company Limited has a diverse portfolio, engaging in research and development across various therapeutic areas, including gastroenterology, rare diseases, and oncology, which can provide multiple revenue streams.

Cons of Takeda Pharmaceutical

  • The stock has experienced volatility, with a 1-year low of $12.57 and a high of $15.08, indicating potential risks associated with price fluctuations.
  • Takeda Pharmaceutical Company Limited has a relatively high price-to-earnings (P/E) ratio of 33.14, which may suggest that the stock is overvalued compared to its earnings.
  • The company has a debt-to-equity ratio of 0.63, which, while manageable, indicates that it relies on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.19 billion
P/E Ratio
33.15
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
1.97 million shares
Average Volume
2.01 million shares
Today's Range
$13.19
$13.29
50-Day Range
$12.91
$13.81
52-Week Range
$12.57
$15.08
Dividend Yield
3.93%
Alnylam Pharmaceuticals stock logo

17. Alnylam Pharmaceuticals NASDAQ:ALNY

$265.96 -3.03 (-1.13%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$269.69 +3.73 (+1.40%)
As of 02/12/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance. Notably, Canaccord Genuity Group recently raised their price objective to $384.00, suggesting significant upside potential.
  • The current stock price is $275.54, which is well above its one-year low of $141.98, indicating a recovery and potential for further growth.
  • Institutional investors own approximately 92.97% of Alnylam Pharmaceuticals, Inc.'s stock, reflecting strong institutional confidence and support for the company's long-term prospects.

Cons of Alnylam Pharmaceuticals

  • The company reported a loss of $0.87 earnings per share (EPS) in its latest quarterly earnings, which was below the consensus estimate, indicating potential challenges in profitability.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio of 31.64, suggesting that the company is heavily reliant on debt financing, which can be risky if market conditions change.
  • Despite a strong institutional backing, there is one analyst rating the stock as a sell, which could indicate concerns about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.30 billion
P/E Ratio
-101.51
Consensus Rating
Moderate Buy
Consensus Price Target
$298.61 (+12.3% Upside)
Volume
820,712 shares
Average Volume
676,999 shares
Today's Range
$261.69
$268.20
50-Day Range
$233.15
$278.99
52-Week Range
$141.98
$304.39
Dividend Yield
N/A
Beigene stock logo

18. Beigene NASDAQ:ONC

$223.31 +2.09 (+0.94%)
As of 02/12/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Market Capitalization
$21.84 billion
P/E Ratio
-27.10
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
221,817 shares
Average Volume
327,443 shares
Today's Range
$221.34
$226.68
50-Day Range
N/A
52-Week Range
$126.97
$248.16
Dividend Yield
N/A
Royalty Pharma stock logo

19. Royalty Pharma NASDAQ:RPRX

$32.34 +0.09 (+0.28%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$32.36 +0.02 (+0.08%)
As of 02/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Market Capitalization
$19.05 billion
P/E Ratio
16.76
Consensus Rating
Buy
Consensus Price Target
$41.67 (+28.8% Upside)
Volume
3.66 million shares
Average Volume
4.20 million shares
Today's Range
$31.73
$32.56
50-Day Range
$24.28
$32.25
52-Week Range
$24.05
$32.72
Dividend Yield
2.68%
Teva Pharmaceutical Industries stock logo

20. Teva Pharmaceutical Industries NYSE:TEVA

$16.33 -0.26 (-1.57%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$16.44 +0.11 (+0.67%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$18.50 billion
P/E Ratio
-11.26
Consensus Rating
Moderate Buy
Consensus Price Target
$23.57 (+44.3% Upside)
Volume
12.96 million shares
Average Volume
13.00 million shares
Today's Range
$16.13
$16.49
50-Day Range
$16.50
$22.77
52-Week Range
$12.51
$22.80
Dividend Yield
N/A
United Therapeutics stock logo

21. United Therapeutics NASDAQ:UTHR

$370.74 +17.43 (+4.93%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$372.78 +2.04 (+0.55%)
As of 02/12/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Market Capitalization
$16.55 billion
P/E Ratio
16.28
Consensus Rating
Moderate Buy
Consensus Price Target
$382.08 (+3.1% Upside)
Volume
626,644 shares
Average Volume
330,398 shares
Today's Range
$350.24
$370.89
50-Day Range
$345.64
$379.69
52-Week Range
$211.61
$417.82
Dividend Yield
N/A
Summit Therapeutics stock logo

22. Summit Therapeutics NASDAQ:SMMT

$19.57 +0.49 (+2.57%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$19.64 +0.07 (+0.33%)
As of 02/12/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Market Capitalization
$14.43 billion
P/E Ratio
-69.89
Consensus Rating
Moderate Buy
Consensus Price Target
$33.57 (+71.5% Upside)
Volume
2.10 million shares
Average Volume
2.27 million shares
Today's Range
$18.42
$19.62
50-Day Range
$16.65
$24.65
52-Week Range
$2.10
$33.89
Dividend Yield
N/A
Insmed stock logo

23. Insmed NASDAQ:INSM

$79.60 -0.29 (-0.36%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$79.62 +0.02 (+0.03%)
As of 02/12/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$14.24 billion
P/E Ratio
-14.34
Consensus Rating
Buy
Consensus Price Target
$85.60 (+7.5% Upside)
Volume
1.39 million shares
Average Volume
1.91 million shares
Today's Range
$78.53
$80.28
50-Day Range
$65.25
$81.44
52-Week Range
$21.92
$82.04
Dividend Yield
N/A
Intra-Cellular Therapies stock logo

24. Intra-Cellular Therapies NASDAQ:ITCI

$127.97 +0.41 (+0.32%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$128.06 +0.09 (+0.07%)
As of 02/12/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Market Capitalization
$13.61 billion
P/E Ratio
-147.09
Consensus Rating
Moderate Buy
Consensus Price Target
$103.62 (-19.0% Downside)
Volume
3.15 million shares
Average Volume
4.68 million shares
Today's Range
$127.45
$127.99
50-Day Range
$81.78
$127.56
52-Week Range
$62.78
$128.00
Dividend Yield
N/A
Genmab A/S stock logo

25. Genmab A/S NASDAQ:GMAB

$19.69 +0.80 (+4.24%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$20.00 +0.31 (+1.55%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Market Capitalization
$13.03 billion
P/E Ratio
19.12
Consensus Rating
Moderate Buy
Consensus Price Target
$45.20 (+129.6% Upside)
Volume
1.62 million shares
Average Volume
1.54 million shares
Today's Range
$18.74
$19.71
50-Day Range
$18.69
$22.19
52-Week Range
$18.64
$31.88
Dividend Yield
N/A
Viatris stock logo

26. Viatris NASDAQ:VTRS

$10.60 -0.01 (-0.09%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$10.59 -0.01 (-0.09%)
As of 02/12/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Market Capitalization
$12.65 billion
P/E Ratio
-14.32
Consensus Rating
Hold
Consensus Price Target
$13.67 (+28.9% Upside)
Volume
8.53 million shares
Average Volume
9.62 million shares
Today's Range
$10.52
$10.65
50-Day Range
$10.60
$12.89
52-Week Range
$9.93
$13.62
Dividend Yield
4.40%
BioMarin Pharmaceutical stock logo

27. BioMarin Pharmaceutical NASDAQ:BMRN

$65.86 +2.31 (+3.63%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$64.91 -0.95 (-1.44%)
As of 02/12/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Market Capitalization
$12.55 billion
P/E Ratio
39.44
Consensus Rating
Moderate Buy
Consensus Price Target
$94.20 (+43.0% Upside)
Volume
1.19 million shares
Average Volume
1.53 million shares
Today's Range
$62.94
$65.92
50-Day Range
$61.25
$68.38
52-Week Range
$60.63
$94.85
Dividend Yield
N/A
Dr. Reddy's Laboratories stock logo

28. Dr. Reddy's Laboratories NYSE:RDY

$13.82 +0.01 (+0.07%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$13.81 -0.01 (-0.07%)
As of 02/12/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Market Capitalization
$11.54 billion
P/E Ratio
22.01
Consensus Rating
Moderate Buy
Consensus Price Target
$17.00 (+23.0% Upside)
Volume
1.90 million shares
Average Volume
1.99 million shares
Today's Range
$13.73
$13.83
50-Day Range
$13.52
$15.86
52-Week Range
$13.36
$16.89
Dividend Yield
0.58%
Sarepta Therapeutics stock logo

29. Sarepta Therapeutics NASDAQ:SRPT

$109.81 +0.13 (+0.12%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$108.69 -1.12 (-1.02%)
As of 02/12/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Market Capitalization
$10.49 billion
P/E Ratio
87.85
Consensus Rating
Moderate Buy
Consensus Price Target
$176.77 (+61.0% Upside)
Volume
639,513 shares
Average Volume
809,954 shares
Today's Range
$108.17
$110.34
50-Day Range
$109.68
$129.00
52-Week Range
$102.15
$173.25
Dividend Yield
N/A
Jazz Pharmaceuticals stock logo

30. Jazz Pharmaceuticals NASDAQ:JAZZ

$135.44 +5.46 (+4.20%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$136.57 +1.13 (+0.84%)
As of 02/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Market Capitalization
$8.19 billion
P/E Ratio
19.08
Consensus Rating
Moderate Buy
Consensus Price Target
$177.00 (+30.7% Upside)
Volume
1.61 million shares
Average Volume
584,775 shares
Today's Range
$128.61
$136.55
50-Day Range
$120.07
$135.44
52-Week Range
$99.06
$136.55
Dividend Yield
N/A
Ascendis Pharma A/S stock logo

31. Ascendis Pharma A/S NASDAQ:ASND

$126.14 +6.63 (+5.55%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$139.00 +12.86 (+10.20%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Market Capitalization
$7.66 billion
P/E Ratio
-15.61
Consensus Rating
Moderate Buy
Consensus Price Target
$191.57 (+51.9% Upside)
Volume
838,248 shares
Average Volume
456,285 shares
Today's Range
$118.03
$127.62
50-Day Range
$119.49
$140.40
52-Week Range
$111.09
$161.00
Dividend Yield
N/A
Roivant Sciences stock logo

32. Roivant Sciences NASDAQ:ROIV

$10.44 -0.05 (-0.48%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$10.59 +0.15 (+1.45%)
As of 02/12/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Market Capitalization
$7.60 billion
P/E Ratio
1.85
Consensus Rating
Buy
Consensus Price Target
$17.93 (+71.7% Upside)
Volume
4.02 million shares
Average Volume
4.30 million shares
Today's Range
$10.33
$10.67
50-Day Range
$10.44
$12.36
52-Week Range
$9.76
$13.06
Dividend Yield
N/A
Madrigal Pharmaceuticals stock logo

33. Madrigal Pharmaceuticals NASDAQ:MDGL

$340.17 +8.38 (+2.53%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$338.83 -1.34 (-0.40%)
As of 02/12/2025 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Market Capitalization
$7.42 billion
P/E Ratio
-13.56
Consensus Rating
Moderate Buy
Consensus Price Target
$351.67 (+3.4% Upside)
Volume
457,285 shares
Average Volume
438,939 shares
Today's Range
$325.87
$340.18
50-Day Range
$272.79
$340.14
52-Week Range
$189.00
$368.29
Dividend Yield
N/A
Corcept Therapeutics stock logo

34. Corcept Therapeutics NASDAQ:CORT

$70.15 +2.04 (+3.00%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$69.95 -0.20 (-0.29%)
As of 02/12/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Market Capitalization
$7.35 billion
P/E Ratio
55.68
Consensus Rating
Buy
Consensus Price Target
$88.25 (+25.8% Upside)
Volume
641,148 shares
Average Volume
852,447 shares
Today's Range
$66.28
$70.68
50-Day Range
$49.85
$70.15
52-Week Range
$20.84
$71.29
Dividend Yield
N/A
Blueprint Medicines stock logo

35. Blueprint Medicines NASDAQ:BPMC

$103.56 +1.99 (+1.96%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$101.78 -1.78 (-1.72%)
As of 02/12/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Market Capitalization
$6.58 billion
P/E Ratio
-49.08
Consensus Rating
Moderate Buy
Consensus Price Target
$123.72 (+19.5% Upside)
Volume
1.15 million shares
Average Volume
976,568 shares
Today's Range
$99.08
$104.92
50-Day Range
$86.82
$115.63
52-Week Range
$72.24
$121.90
Dividend Yield
N/A
Legend Biotech stock logo

36. Legend Biotech NASDAQ:LEGN

$35.87 +1.24 (+3.58%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$35.92 +0.05 (+0.15%)
As of 02/12/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Market Capitalization
$6.55 billion
P/E Ratio
-37.76
Consensus Rating
Buy
Consensus Price Target
$79.50 (+121.6% Upside)
Volume
787,580 shares
Average Volume
1.30 million shares
Today's Range
$34.36
$35.97
50-Day Range
$31.43
$42.45
52-Week Range
$30.17
$70.13
Dividend Yield
N/A
Axsome Therapeutics stock logo

37. Axsome Therapeutics NASDAQ:AXSM

$131.55 -0.65 (-0.49%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$130.75 -0.80 (-0.61%)
As of 02/12/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Market Capitalization
$6.37 billion
P/E Ratio
-20.15
Consensus Rating
Buy
Consensus Price Target
$147.13 (+11.8% Upside)
Volume
1.11 million shares
Average Volume
1.11 million shares
Today's Range
$128.26
$133.10
50-Day Range
$80.05
$132.20
52-Week Range
$64.11
$134.18
Dividend Yield
N/A
BridgeBio Pharma stock logo

38. BridgeBio Pharma NASDAQ:BBIO

$31.95 +0.83 (+2.67%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$31.78 -0.17 (-0.54%)
As of 02/12/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Market Capitalization
$6.04 billion
P/E Ratio
-13.26
Consensus Rating
Moderate Buy
Consensus Price Target
$49.08 (+53.6% Upside)
Volume
1.29 million shares
Average Volume
2.74 million shares
Today's Range
$30.50
$32.01
50-Day Range
$25.98
$37.59
52-Week Range
$21.62
$41.04
Dividend Yield
N/A
Telix Pharmaceuticals Limited American Depositary Shares stock logo

39. Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$17.60 -0.04 (-0.23%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$17.00 -0.60 (-3.41%)
As of 02/12/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Market Capitalization
$5.94 billion
P/E Ratio
N/A
Consensus Rating
Strong Buy
Consensus Price Target
$22.00 (+25.0% Upside)
Volume
17,369 shares
Average Volume
15,560 shares
Today's Range
$17.23
$17.72
50-Day Range
$14.56
$18.90
52-Week Range
$14.01
$19.99
Dividend Yield
N/A
Nuvalent stock logo

40. Nuvalent NASDAQ:NUVL

$81.24 -1.66 (-2.00%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$82.04 +0.80 (+0.98%)
As of 02/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Market Capitalization
$5.89 billion
P/E Ratio
-23.41
Consensus Rating
Moderate Buy
Consensus Price Target
$112.36 (+38.3% Upside)
Volume
366,187 shares
Average Volume
485,007 shares
Today's Range
$80.31
$82.44
50-Day Range
$72.09
$94.31
52-Week Range
$61.79
$113.51
Dividend Yield
N/A
Elanco Animal Health stock logo

41. Elanco Animal Health NYSE:ELAN

$11.38 -0.03 (-0.26%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$11.59 +0.21 (+1.85%)
As of 02/12/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Market Capitalization
$5.63 billion
P/E Ratio
28.45
Consensus Rating
Hold
Consensus Price Target
$16.29 (+43.1% Upside)
Volume
2.75 million shares
Average Volume
4.65 million shares
Today's Range
$11.24
$11.52
50-Day Range
$11.38
$12.88
52-Week Range
$11.11
$18.80
Dividend Yield
N/A
Alkermes stock logo

42. Alkermes NASDAQ:ALKS

$33.50 +1.54 (+4.82%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$33.93 +0.43 (+1.28%)
As of 02/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Market Capitalization
$5.42 billion
P/E Ratio
17.18
Consensus Rating
Moderate Buy
Consensus Price Target
$36.33 (+8.5% Upside)
Volume
3.57 million shares
Average Volume
1.62 million shares
Today's Range
$31.33
$33.73
50-Day Range
$28.08
$31.96
52-Week Range
$22.90
$33.73
Dividend Yield
N/A
Verona Pharma stock logo

43. Verona Pharma NASDAQ:VRNA

$62.70 +3.37 (+5.68%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$63.48 +0.77 (+1.24%)
As of 02/12/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Market Capitalization
$5.01 billion
P/E Ratio
-32.66
Consensus Rating
Buy
Consensus Price Target
$57.14 (-8.9% Downside)
Volume
1.80 million shares
Average Volume
1.55 million shares
Today's Range
$58.69
$63.50
50-Day Range
$39.26
$61.37
52-Week Range
$11.39
$63.50
Dividend Yield
N/A
Cytokinetics stock logo

44. Cytokinetics NASDAQ:CYTK

$42.18 +0.62 (+1.49%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$41.26 -0.92 (-2.19%)
As of 02/12/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Market Capitalization
$4.98 billion
P/E Ratio
-7.84
Consensus Rating
Moderate Buy
Consensus Price Target
$83.00 (+96.8% Upside)
Volume
1.79 million shares
Average Volume
1.42 million shares
Today's Range
$40.53
$42.33
50-Day Range
$41.56
$50.96
52-Week Range
$40.53
$81.36
Dividend Yield
N/A
Ionis Pharmaceuticals stock logo

45. Ionis Pharmaceuticals NASDAQ:IONS

$30.84 -0.74 (-2.34%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$30.84 0.00 (0.00%)
As of 02/12/2025 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Market Capitalization
$4.87 billion
P/E Ratio
-12.64
Consensus Rating
Moderate Buy
Consensus Price Target
$60.65 (+96.7% Upside)
Volume
1.23 million shares
Average Volume
1.57 million shares
Today's Range
$30.37
$31.56
50-Day Range
$30.84
$38.58
52-Week Range
$30.37
$52.34
Dividend Yield
N/A
Grifols stock logo

46. Grifols NASDAQ:GRFS

$7.01 -0.18 (-2.50%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$6.91 -0.10 (-1.48%)
As of 02/12/2025 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Market Capitalization
$4.82 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
702,991 shares
Average Volume
799,930 shares
Today's Range
$6.98
$7.20
50-Day Range
$6.62
$8.05
52-Week Range
$5.30
$9.96
Dividend Yield
N/A
TG Therapeutics stock logo

47. TG Therapeutics NASDAQ:TGTX

$30.90 -0.21 (-0.68%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$30.92 +0.03 (+0.08%)
As of 02/12/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Market Capitalization
$4.81 billion
P/E Ratio
-308.97
Consensus Rating
Moderate Buy
Consensus Price Target
$40.67 (+31.6% Upside)
Volume
1.46 million shares
Average Volume
2.33 million shares
Today's Range
$30.31
$31.05
50-Day Range
$27.67
$34.40
52-Week Range
$12.84
$36.84
Dividend Yield
N/A
Biohaven stock logo

48. Biohaven NYSE:BHVN

$42.09 -0.44 (-1.03%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$42.02 -0.07 (-0.15%)
As of 02/12/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Market Capitalization
$4.26 billion
P/E Ratio
-4.50
Consensus Rating
Buy
Consensus Price Target
$63.15 (+50.0% Upside)
Volume
867,962 shares
Average Volume
945,277 shares
Today's Range
$40.62
$42.63
50-Day Range
$35.34
$44.80
52-Week Range
$26.80
$62.21
Dividend Yield
N/A
Prestige Consumer Healthcare stock logo

49. Prestige Consumer Healthcare NYSE:PBH

$84.18 -1.78 (-2.07%)
Closing price 02/12/2025 03:59 PM Eastern
Extended Trading
$84.26 +0.08 (+0.10%)
As of 02/12/2025 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Market Capitalization
$4.16 billion
P/E Ratio
19.71
Consensus Rating
Moderate Buy
Consensus Price Target
$92.50 (+9.9% Upside)
Volume
299,858 shares
Average Volume
319,849 shares
Today's Range
$84.16
$85.56
50-Day Range
$73.91
$87.29
52-Week Range
$62.35
$88.36
Dividend Yield
N/A
Ultragenyx Pharmaceutical stock logo

50. Ultragenyx Pharmaceutical NASDAQ:RARE

$43.43 -0.15 (-0.34%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$43.12 -0.31 (-0.70%)
As of 02/12/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Market Capitalization
$4.01 billion
P/E Ratio
-6.71
Consensus Rating
Moderate Buy
Consensus Price Target
$92.43 (+112.8% Upside)
Volume
635,030 shares
Average Volume
901,148 shares
Today's Range
$42.52
$43.74
50-Day Range
$40.00
$49.38
52-Week Range
$37.02
$60.37
Dividend Yield
N/A